SEC Form 4 · accession 0001179110-15-013772
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Martin
Officer — Chairman and CEO · Director
Period of report
Oct 1, 2015
Accepted (ET)
Oct 5, 2015 · 1:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 1, 2015 | M | 150,000 | $14.5025 | A | 4,098,066 | D | |
| Common StockF3 | Oct 1, 2015 | S | 87,500 | $97.1353 | D | 4,010,566 | D | |
| Common StockF4 | Oct 1, 2015 | S | 62,500 | $97.9672 | D | 3,948,066 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock option (right to buy)F2 | $14.5025 | Oct 1, 2015 | M | 150,000 | D | — | Jan 25, 2016 | Common Stock | 150,000 | 300,000 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $96.54 to $97.54. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $97.55 to $98.48. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.